Opinion|Videos|February 27, 2026

Fred Saad, MD, highlights phase 1 study of 225Ac-PSMA-Trillium in mCRPC

Fact checked by: Hannah Clarke

Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.

In this video, Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study, assessing the investigational alpha-emitting radioligand therapy 225Ac-PSMA-Trillium (BAY 3563254) in patients with metastatic castration-resistant prostate cancer (mCRPC). These results were presented at the 2026 ASCO Genitourinary (GU) Cancers Symposium in San Francisco, California.

Saad is a professor and chief of urology at University of Montreal Hospital Center.